Nuvalent Inc Dossier - Source-backed chat

Nuvalent Inc

NUVLNASDAQ

SectorHealthcare

IndustryBiotechnology

Beta (adjusted)1.09

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $123.96Price as of 14 Jul 2026

Data confidence Sign in to view data confidence

Market Cap $9.8B

Shares Outstanding 79.7M diluted

Next Earnings Date27 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Nuvalent is no longer an independently investable public company. GSK completed its acquisition on July 15, 2026 after agreeing to pay $124 in cash for each outstanding Nuvalent share. Jideytro was approved by the FDA on July 22, 2026, while neladalkib remained under FDA review as of August 31, 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$124.00

Mean target$124.00

High · most bullish analyst$124.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$124.005%

An unfavorable neladalkib regulatory outcome or weaker-than-expected performance from the acquired assets could reduce their value to GSK, but it would not reduce the $124 cash consideration already paid to former Nuvalent shareholders.

Base CaseCentral scenario

$124.0090%

Matches the consensus mean

The completed tender offer and merger fixed the realizable value for former Nuvalent shareholders at $124 per share.

Bull CaseUpside scenario

$124.005%

The historical transaction value remains $124 per former Nuvalent share because the acquisition has closed. Strong commercialization of Jideytro and a favorable neladalkib decision could validate the strategic value of the acquired pipeline, but any incremental upside belongs to GSK rather than former Nuvalent equity holders.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Completion of the acquisition eliminated transaction-closing risk and crystallized $124 per share in cash for former Nuvalent shareholders.
FDA approval of Jideytro shortly after closing clinically validated one of the principal assets acquired by GSK.

Key Investment Risks

Nuvalent no longer offers an independently traded security, preventing new investors from obtaining direct exposure to its former pipeline.
Neladalkib remained subject to FDA review, but its regulatory and commercial risks now accrue to GSK rather than former Nuvalent shareholders.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.